Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Tech is Caixin Global's real-time tech news portal, featuring 24-hour news, short-form analysis, and roundups from business and tech media in China.

LATEST
Britain Bans Installation of New Huawei 5G Equipment from September 2021 in Major U-Turn
Chinese Investors Bullish About Space as Satellite Startup Pockets $375 Million in Pre-IPO Funding Round
Fashion E-Retailer Mogu Gets Livestreaming Lift in Otherwise Dismal Quarter
Chinese-Focused Food Delivery App HungryPanda Raises $70m
Trending in China: Should Chinese School Employees be Punished for Celebrating Thanksgiving?
China Exempts Tesla Model Y from Purchase Tax
GL Ventures Leads $265m Series C Round in Chinese SaaS Edtech Firm EEO
In 165 countries, China's Beidou eclipses American GPS
China On Cusp of Becoming Third Ever Country to Collect Lunar Samples as Chang’e 5 Prepares for Moon Landing
JD.com Among Bidders for Japanese Skincare Brand Fancl’s Asian Business: Reuters
Trending in China: Did Sichuan Forget to Tell Chongqing About Their Joint Olympic Bid?
Alibaba’s Healthcare Unit Finds Tonic for Profits
Trending in China: Beijing Tackles Parking Shortage With Shared Spaces
Chinese Wireless Telecoms Operators Join Forces to Build 5G Base Stations to Reduce Costs
Ruhnn, Another U.S.-Listed Chinese Company Looks to Go Private
Unicorns surge to 500 in number as US and China account for 70%
Trending in China: Social Media Comes Out in Support of High Quality Fakes
Xiaomi-Backed IoT-Enabled Appliance Maker Sees Revenues Grow While Profits Slump
Chinese Startup WeRide Reports Promising Robotaxi Results
Trending in China: God recalls his hand – tributes to Maradona from Chinese social media after his death
Chinese Biotech Startup D3 Bio Raises $200 Million in Series A Round

Eudora Wang / Nov 19, 2020 07:12 PM / Business & Tech

Chinese biotech startup D3 Bio, a precision medicine developer, has closed its Series A funding round at $200 million to support the development of the firm’s portfolio in oncology and immunology.

Chinese private equity firm Boyu Capital, Matrix Partners China, Sequoia Capital China, Singapore state investor Temasek and Hong Kong-listed pharma WuXi AppTec’ corporate venture fund joined the round.

In a filing to the Hong Kong stock exchange on the same day, WuXi AppTec disclosed that it agreed to invest $21 million for 21 million Series A-1 shares in D3 Bio, which represents nearly 16.7 per cent of the startup’s issued share capital.

“D3 Bio employs a new approach, surveying the clinical landscape rather than only following laboratory insights, to identify the unmet patient needs and to match patients with optimal therapies,” said WuXi AppTec in the filing.

Harnessing insights from clinical development, D3 Bio identifies new disease targets and delivery methods in immunology and oncology to match patients with optimal therapies to treat their diseases.

The startup said that having a clear understanding during preclinical development both of relevant cancer biomarkers and the therapeutic improvement or replacement goals will make drug discovery and development “as efficient and focused as possible.”

D3 Bio was co-founded by George Chen, an oncologist veteran who previously held senior positions at firms such as Eli Lilly, Johnson & Johnson, and the National Institutes of Health. The other co-founder, John Jin, is a founding partner at healthcare-focused PE firm Hanne Capital and a former executive at Chinese biotech firm BeiGene and Taipei-based TaiGen Biotechnology.

Before the Series A round, Chen and Jin held a 55 per cent stake and a 45 per cent stake respectively in D3 Bio, according to WuXi AppTec’s filing.

“D3 Bio intends to create a robust portfolio comprised of internal core assets that can be leveraged for follow-on development as well as in-licensed early-stage clinical assets,” said Chen.’

This article was originally published by Deal Street Asia

 


Share this article
Open WeChat and scan the QR code